CoV-2 nucleocapsid antibodies to detect exposure to SARS-CoV-2: results from a prospective cohort study on COVID-19 ...

In a Swedish cohort, the risk of long COVID was much lower for vaccinated than unvaccinated participants in the year after ...

In general, VRBPAC almost always recommends the same influenza strains as the World Health Organization (WHO) for egg-based ...

Vaccine skeptics have long-since leveraged the rapid roll out of mRNA vaccines to add fuel to heated arguments surrounding ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

Although the bivalent COVID-19 vaccine conferred moderate protection against symptomatic disease, hybrid immunity provided the strongest protection.

The CDC has issued interim effectiveness estimates for the 2024-2025 seasonal influenza and 2024-2025 COVID-19 vaccines.

Although several vaccines and drugs are available against SARS-CoV-2, the search for effective therapeutic agents for COVID-19 and future zoonotic coronaviruses continues. The RNA-dependent RNA ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

New inhaled COVID-19 vaccine by McMaster enters phase-2 trials in Canada. The vaccine aims to provide stronger, needle-free ...

Cornell researchers have developed a stable, multi-target vaccine offering long-lasting protection against COVID-19 and influenza, with promising results in mice. Cornell University researchers have ...